Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
J Cardiovasc Pharmacol
    October 2026
  1. POLLESELLO P, Papp Z
    Fifty Years of Non-Adrenergic Inotropes in Heart Failure.
    J Cardiovasc Pharmacol. 2026 Oct 16. doi: 10.1097/FJC.0000000000001892.
    >> Share

    September 2026
  2. LOTAN D, Elad B, Lee C, Richter I, et al
    The Novelty of Anticoagulation in LVAD Therapy: Current Practice, the Role of Direct Oral Anticoagulants, and Future Directions.
    J Cardiovasc Pharmacol. 2026;88:190-197.
    >> Share

    August 2026
  3. BOGIN V, Weir MR
    Eplerenone Revisited: A Balanced Reappraisal of Its Role in Hypertension, Heart Failure, and Cardiorenal Disease.
    J Cardiovasc Pharmacol. 2026 Aug 19. doi: 10.1097/FJC.0000000000001875.
    >> Share

    July 2026
  4. KELLY J, Mezzaroma E, Roscioni A, McSkimming C, et al
    INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA.
    J Cardiovasc Pharmacol. 2026 Jul 1. doi: 10.1097/FJC.0000000000001849.
    >> Share

    June 2026
  5. LOEB SA, Tharp DL, Zawieja SD, Pal S, et al
    Pitfalls of therapies targeting the nitric oxide signaling pathway in heart failure with preserved ejection fraction.
    J Cardiovasc Pharmacol. 2026 Jun 22. doi: 10.1097/FJC.0000000000001844.
    >> Share

    April 2026
  6. ABDELHAMID A, Arabi A, Rajha H, Tluli O, et al
    Efficacy and Safety of the beta3-Adrenergic Agonist Mirabegron in Patients with Heart Failure: An Updated Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2026 Apr 8. doi: 10.1097/FJC.0000000000001821.
    >> Share

  7. WANG YQ, Deng QY, Zhang ZZ, Wang GL, et al
    Short-Term Effect of Levosimendan in Acute Right Heart Failure Caused by Pulmonary Hypertension: A Pilot Study.
    J Cardiovasc Pharmacol. 2026 Apr 8. doi: 10.1097/FJC.0000000000001824.
    >> Share

    February 2026
  8. SARTO G, Simeone B, Sbandi F, Valenti V, et al
    Magnitude of blood pressure reduction in response to levosimendan infusion independently predicts in-hospital mortality in patients with acute heart failure.
    J Cardiovasc Pharmacol. 2026 Feb 23. doi: 10.1097/FJC.0000000000001811.
    >> Share

  9. YAO S, Zhang H, Li M, Han S, et al
    Integrating Network Pharmacology and In Vitro 3D Cardiac Organoid Model Validation to Investigate the Action Mechanism of Shenfu Xiangshao Decoction on Heart Failure.
    J Cardiovasc Pharmacol. 2026 Feb 20. doi: 10.1097/FJC.0000000000001802.
    >> Share

    January 2026
  10. SEMENYCHEVA I, Larina S, Zakharova L, Vakolyuk R, et al
    Safety of Repeated Levosimendan Use in Chronic Heart Failure.
    J Cardiovasc Pharmacol. 2026 Jan 22. doi: 10.1097/FJC.0000000000001797.
    >> Share

    December 2025
  11. ELAD B, Lotan D, Richter I, Changhee L, et al
    Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Real-World Insights from Pressure Sensor Monitoring.
    J Cardiovasc Pharmacol. 2025 Dec 11. doi: 10.1097/FJC.0000000000001761.
    >> Share

  12. BERNARDI M, Golino M, Spadafora L, Sarto G, et al
    Current Challenges for the Diagnosis of HFpEF and Possible Simplification of the Diagnostic Approach.
    J Cardiovasc Pharmacol. 2025;86:522-534.
    >> Share

  13. SONG C, Tang Q, Liu L, Zhou G, et al
    CDK Inhibitor R547 Attenuates Pressure Overload-Induced Cardiac Hypertrophy Through PI3K/AKT and TGF-beta/Smad3 Signaling Pathways.
    J Cardiovasc Pharmacol. 2025;86:557-564.
    >> Share

    November 2025
  14. XIE Y, Huang T, Wang H, Yang J, et al
    Lactylation-Related Gene Signature and Immune Infiltration Crosstalk in Heart Failure: Insights from Bulk and Single-Cell Transcriptomics.
    J Cardiovasc Pharmacol. 2025 Nov 18. doi: 10.1097/FJC.0000000000001775.
    >> Share

    October 2025
  15. ACOSTA C, Anderson HD, Anderson CM
    Disparate mechanical and functional properties of spontaneously hypertensive rat (SHR) and spontaneously hypertensive heart failure (SHHF) rat penetrating arterioles.
    J Cardiovasc Pharmacol. 2025 Oct 31. doi: 10.1097/FJC.0000000000001770.
    >> Share

  16. NILO D, Gualdiero F, Russo V, Zielinska K, et al
    Commentary On the Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials.
    J Cardiovasc Pharmacol. 2025 Oct 10. doi: 10.1097/FJC.0000000000001767.
    >> Share

    September 2025
  17. HOGWOOD AC, Golino M, Moroni F, Canada JM, et al
    The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials.
    J Cardiovasc Pharmacol. 2025 Sep 9. doi: 10.1097/FJC.0000000000001756.
    >> Share

    August 2025
  18. GALLUZZO A, Bertaina M, Vishram-Nielsen JKK, Camilli M, et al
    Current Practices and Perspectives on the Use of Intravenous Vasodilators in Acute Heart Failure: An International Survey.
    J Cardiovasc Pharmacol. 2025 Aug 20. doi: 10.1097/FJC.0000000000001753.
    >> Share

  19. WEN S, Liu X, Liu L, Hu Y, et al
    Landscape of Berberine Targets: A Potential Pharmacological Insight for Heart failure Treatment.
    J Cardiovasc Pharmacol. 2025 Aug 20. doi: 10.1097/FJC.0000000000001750.
    >> Share

    June 2025
  20. ABBATE A
    Heart failure with preserved ejection fraction: how far we've come - a brief report from two outstanding educational events.
    J Cardiovasc Pharmacol. 2025 Jun 27. doi: 10.1097/FJC.0000000000001733.
    >> Share

  21. WU Y, Song M, Chen W, Liang F, et al
    miR-132 inhibition improves cardiac remodeling and function in a two-hit mouse model of heart failure with a preserved ejection fraction.
    J Cardiovasc Pharmacol. 2025 Jun 18. doi: 10.1097/FJC.0000000000001729.
    >> Share

    May 2025
  22. ZHANG J, Chen X, Wan C
    Aerobic exercise rehabilitation training alleviates skeletal muscle atrophy caused by heart failure in mice through the SIRT1/PGC-1alpha pathway.
    J Cardiovasc Pharmacol. 2025 May 28. doi: 10.1097/FJC.0000000000001722.
    >> Share

  23. YAMASHITA I, Fujisaki T, Romeo FJ, Sueta D, et al
    Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2025;85:329-337.
    >> Share

    April 2025
  24. CHEN C, Qin X, Cao Y, Qing L, et al
    Flavin adenine dinucleotide ameliorates pressure overload-induced heart failure by activating the short-chain acyl-CoA dehydrogenase.
    J Cardiovasc Pharmacol. 2025 Apr 8. doi: 10.1097/FJC.0000000000001698.
    >> Share

    March 2025
  25. BIONDI-ZOCCAI G, Galli M, Booz GW
    Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction, Erratum.
    J Cardiovasc Pharmacol. 2025;85:238.
    >> Share

    February 2025
  26. GALATI G, Germanova O
    Mineralocorticoid receptor antagonists in end-stage renal disease under renal replacement therapies: bridging the gap between cardiovascular and systemic benefit, from heart failure to myocardial infarction.
    J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677.
    >> Share

    January 2025
  27. DIMITRIADIS K, Pitsiori D, Alexiou P, Pyrpyris N, et al
    Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where There Is Smoke, There Is Fire?
    J Cardiovasc Pharmacol. 2025;85:12-20.
    >> Share

    December 2024
  28. KEFER E, Gulbis B, Weeks P
    Comparison of Urine Output Response of Intravenous Bumetanide and Furosemide in Acute Decompensated Heart Failure: an observational analysis.
    J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001658.
    >> Share

    November 2024
  29. DENICOLAI M, Morello M, Golino M, Corna G, et al
    Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity.
    J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652.
    >> Share

    September 2024
  30. RYUNO Y, Kobayashi JI, Fujimoto Y, Dotare T, et al
    Effect of an Enteral Formula Enriched with omega-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model.
    J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001637.
    >> Share

  31. BIONDI-ZOCCAI G, Galli M, Booz GW
    Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001636.
    >> Share

  32. BIONDI-ZOCCAI G, Frati G, Peruzzi M, Booz GW, et al
    Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2 Inhibitors?
    J Cardiovasc Pharmacol. 2024;84:271-275.
    >> Share

  33. HAJIQASEMI M, Ebrahimzade M, Ghelichkhan ZA, Huang X, et al
    Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review.
    J Cardiovasc Pharmacol. 2024;84:276-288.
    >> Share

    August 2024
  34. HENSON BD, Bale-Neary CA, Mecaskey R, Gbujie O, et al
    SGLT2 Inhibitors, Malnutrition, Cachexia, and Survival in Heart Failure Patients with a History of Anthracycline Treatment.
    J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001620.
    >> Share

  35. GIBSON CM, Beard MM, Escano AK, Good BL, et al
    Metolazone vs chlorothiazide in acute heart failure patients with diuretic resistance and renal dysfunction: a retrospective cohort study.
    J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001623.
    >> Share

    July 2024
  36. LINGYAN Z, Zijia H, Ya Z, Ying Z, et al
    Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure Patients: An Updated Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610.
    >> Share

  37. ZHANG X, Sun G, Li Z, Gao W, et al
    Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;84:18-25.
    >> Share

  38. LIU TH, Hsieh RJ, Chen HH, Kuo TJ, et al
    Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through p38-MAPK Pathways.
    J Cardiovasc Pharmacol. 2024;84:110-117.
    >> Share

    May 2024
  39. HOU B, Yu D, Bai H, Du X, et al
    Research progress of miRNA in heart failure: prediction and treatment.
    J Cardiovasc Pharmacol. 2024 May 3. doi: 10.1097/FJC.0000000000001588.
    >> Share

    April 2024
  40. BARBIERO R, Pennella B, Bonaventura A
    The long-standing search for albumin placement in acute heart failure.
    J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001580.
    >> Share

  41. KAKZANOV Y, Sevilya Z, Goldman A, Cipok M, et al
    The Effect of SGLT2 Inhibitor Therapy on Endothelial Progenitor Cell Function in Patients with Heart Failure.
    J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001581.
    >> Share

  42. POLLESELLO P
    Repetitive treatments with inotropes in advanced heart failure.
    J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001569.
    >> Share


  43. The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Erratum.
    J Cardiovasc Pharmacol. 2024;83:359.
    >> Share

    March 2024
  44. ZHANG X, Wang Z, Zhang L, Zhao X, et al
    Comparative effectiveness and safety of intermittent, repeated or continuous use of levosimendan, milrinone, or dobutamine in patients with advanced heart failure: a network and single-arm meta-analysis.
    J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001561.
    >> Share

  45. ZOHORI BAHRAMI HS, Hasselbalch RB, Soholm H, Thomsen JH, et al
    First-in-man trial of beta3-adrenoceptor agonist treatment in chronic heart failure - impact on diastolic function.
    J Cardiovasc Pharmacol. 2024 Mar 5. doi: 10.1097/FJC.0000000000001545.
    >> Share

    January 2024
  46. HUANG Y, Zhou H, Fang C, Ma L, et al
    Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China.
    J Cardiovasc Pharmacol. 2024;83:86-92.
    >> Share

    December 2023
  47. SCOMA CB, Lee DH, Money D, Eichelberger G, et al
    The Impact of Midodrine On Guideline-Directed Medical Therapy in Patients Admitted with Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2023 Dec 21. doi: 10.1097/FJC.0000000000001532.
    >> Share

    November 2023
  48. SILVETTI S, Pollesello P, Belletti A
    Repeated levosimendan infusions in the management of advanced heart failure: review of the evidence and meta-analysis of the effect on mortality.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001506.
    >> Share

  49. SUN Q, Cui W, Zhang X, Tian Y, et al
    A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517.
    >> Share

  50. LAI M, Lam JC, Radosevich JJ, Patanwala AE, et al
    Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF).
    J Cardiovasc Pharmacol. 2023 Nov 17. doi: 10.1097/FJC.0000000000001513.
    >> Share

  51. KOMMU S
    The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2023 Nov 15. doi: 10.1097/FJC.0000000000001511.
    >> Share

  52. ZHANG X, Wang N, Fu P, An Y, et al
    Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating beta-Hydroxybutyrate-activated Citrate Synthase.
    J Cardiovasc Pharmacol. 2023;82:375-388.
    >> Share

    October 2023
  53. CANTRELL AC, Zeng H, Chen JX
    The therapeutic potential of targeting ferroptosis in the treatment of mitochondrial cardiomyopathies and heart failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001496.
    >> Share

  54. JAFREE E, Del Buono MG, Canada JM, Carbone S, et al
    Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001497.
    >> Share

  55. CAMILLI M, Ballacci F, Giordano F, Minotti G, et al
    Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price?
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001498.
    >> Share

    September 2023
  56. BUONPANE A, Biondi-Zoccai G, Versaci F
    Molecular insights on ischemic heart failure: from core genes to hearts.
    J Cardiovasc Pharmacol. 2023 Sep 26. doi: 10.1097/FJC.0000000000001486.
    >> Share

  57. LIN L, Zicheng L, Shaohua G
    Post-acute myocardial infarction heart failure core genes and relevant signaling pathways.
    J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481.
    >> Share

  58. BROCKMOLLER J, Ivanoski S, Hundack L, Blohm JH, et al
    Clinical and hemodynamic improvement in pulmonary hypertension after switching to sacubitril/valsartan in heart failure patients with preserved ejection fraction.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001477.
    >> Share

  59. PITT B, Rosenson RS
    Statins in patients with established heart failure: Time for reflection.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001475.
    >> Share

    July 2023
  60. PARK S, Chang J, Hong SP, Jin ES, et al
    Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery Revascularization.
    J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453.
    >> Share

    June 2023
  61. HU WS, Lin CL
    Angiotensin receptor-neprilysin inhibitor versus renin-angiotensin system inhibitor for dementia risk in patients with heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 30. doi: 10.1097/FJC.0000000000001451.
    >> Share

  62. AHMAD F, Karim A, Khan J, Qaisar R, et al
    Statin therapy induces gut leakage and neuromuscular disjunction in patients with chronic heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 27. doi: 10.1097/FJC.0000000000001445.
    >> Share

  63. MANILALL A, Mokotedi L, Gunter S, Le Roux R, et al
    Tumor Necrosis Factor-alpha Mediates Inflammation-induced Early-Stage Left Ventricular Systolic Dysfunction.
    J Cardiovasc Pharmacol. 2023;81:411-422.
    >> Share

    May 2023
  64. AUGUSTIN N, Alvarez C, Kluger J
    The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
    J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439.
    >> Share

    April 2023
  65. HU WS, Lin CL
    Association of heart failure patients with and without sacubitril-valsartan use with incident cancer risk.
    J Cardiovasc Pharmacol. 2023 Apr 28. doi: 10.1097/FJC.0000000000001433.
    >> Share

  66. NAKATANI D, Dohi T, Hikoso S, Tanaka A, et al
    Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial.
    J Cardiovasc Pharmacol. 2023 Apr 18. doi: 10.1097/FJC.0000000000001430.
    >> Share

    March 2023
  67. ZHANG H, Huetteman AT, Reyes EA, Appelbaum JS, et al
    Effects of sacubitril-valsartan in Patients with Various Types of Heart Failure: A Meta-Analysis.
    J Cardiovasc Pharmacol. 2023 Mar 31. doi: 10.1097/FJC.0000000000001421.
    >> Share

  68. KUANG N, Shu B, Yang F, Li S, et al
    TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016